Skyrizi and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Acetaminophen, and have Psoriasis.

The phase IV clinical study analyzes which people have Skin hyperpigmentation when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 638 drugs and 812 conditions by eHealthMe. Check the latest studies of Skin hyperpigmentation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 13 people (0.03%) have Skin hyperpigmentation.

Could Skyrizi cause Skin hyperpigmentation?

Among these 13 people:

How long have people been on Skyrizi when they have Skin hyperpigmentation? *

What is the gender of people who have Skin hyperpigmentation when taking Skyrizi? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Skin hyperpigmentation when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

Zolpidem: 2 people, 15.38%
Potassium Chloride: 2 people, 15.38%
Pantoprazole: 2 people, 15.38%
Gabapentin: 2 people, 15.38%
Clopidogrel: 2 people, 15.38%
Allopurinol: 2 people, 15.38%
Acetaminophen: 2 people, 15.38%
Vitamin B6: 1 person, 7.69%
Sertraline Hydrochloride: 1 person, 7.69%
Sertraline: 1 person, 7.69%

What are other side effects people have besides Skin hyperpigmentation? *

Pain: 6 people, 46.15%
Skin Cancer: 5 people, 38.46%
Joint Pain: 4 people, 30.77%
Joint Range Of Motion Decreased (disease of joint movement): 4 people, 30.77%
Insomnia (sleeplessness): 4 people, 30.77%
Grip Strength Decreased: 4 people, 30.77%
Mobility Decreased (ability to move is reduced): 4 people, 30.77%
Poor Quality Sleep: 3 people, 23.08%
Incontinence (lack of moderation or self-control): 3 people, 23.08%
Skin Disorder (skin disease): 3 people, 23.08%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 7 people, 53.85%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 30.77%
Pigmentation Disorder (disturbances of human skin colour): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Skin hyperpigmentation?

- Check whether Skin hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (638 drugs)

Browse all the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (812 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.